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We present a case in which phaeochromocytoma was not diagnosed preoperatively despite extensive investigation. There was
signiﬁcant haemodynamic instability during surgery. We review current diagnostic criteria with a view to reducing such a risk in
future.
1.Introduction
Phaeochromocytoma is a rare catecholamine-secreting tum-
our arising from chromaﬃn tissue. It may precipitate life-
threatening hypertensive crises or cardiac arrhythmias and
so preoperative diagnosis is essential. Mortality associated
with surgery in an undiagnosed phaeochromocytoma is said
to be up to 80% [1]. We present a case of a known adrenal
tumour in which standard preoperative tests failed to diag-
nose phaeochromocytoma. We discuss the range of available
diagnostic tests and make recommendations for their possi-
ble applications.
2.CaseReport
A 54-year-old female presented for laparoscopic adrenalec-
tomy, with a diagnosis of a vascular nonfunctioning adrenal
tumour.
She had originally presented about 18months previously
with an episode of abdominal pain, dizziness, and vomiting.
Blood pressure on admission to hospital was normal, al-
though it was noted in the referral letter from her family
doctor to have been 240/60mmHg with a heart rate of 90
beats per minute.
Her other medical histories included hypercholestero-
laemia, polycystic ovarian syndrome, and morbid obesity
treated with gastric banding 8 months before the current
admission: this had resulted in a weight reduction from
117kg (Body Mass Index, BMI 46.3) to 64.5kg (BMI 25).
She had diabetes mellitus, which had previously been con-
trolled with insulin but since her bariatric surgery had been
controlled with metformin. Her other drug treatment com-
prised fenoﬁbrate, citalopram, vitamin B12, folic acid, and
multivitamins.
Following abdominal ultrasound on admission, she un-
derwent abdominal CT on the same day, followed by a
succession of other imaging modalities because of diagnostic
uncertainty. She also had biochemical tests for phaeochro-
mocytoma, Cushing’s syndrome, and Conn’s syndrome.
Results of imaging and diagnostic tests are summarised in
Table 1.
The anaesthetic technique for the laparoscopic adrena-
lectomy consisted of induction with midazolam 2mg, alfen-
tanil 1mg and propofol 100mg, neuromuscular blockade
with rocuronium 50mg, and maintenance of anaesthesia
with oxygen/air/sevoﬂurane. Fentanyl was given to a total
dose of 400 micrograms, and further rocuronium titrated
against the response to a peripheral nerve stimulator. Blood
pressure monitoring was with an automatic noninvasive
technique, and no central venous pressure monitoring was
used.
During mobilisation of the tumour, blood pressure rose
to 266/124mmHg. Initially this was treated with increased
inspired concentration of sevoﬂurane and increments of2 Case Reports in Anesthesiology
Table 1: Diagnostic tests performed.
Imaging studies
Modality Timing Result
Ultrasound scan Day 0 5 ×4cm mass upper pole of left kidney
CT scan Day 0 5 ×5.7cm L retroperitoneal mass suggestive of haemorrhage into adrenal
cyst
CT scan At 2 months Decrease in size to 3.2 ×3.1cm suggestive of adrenal vascular tumour
CT angiogram At 2 months Vascular L adrenal tumour
CT angiogram At 6 months Further decrease in size to 3 × 2.5cm, with the appearance of a vascular
adrenal tumour
MRI At 8 months Adrenal mass 2.9 ×2.1cm. Not a simple adenoma
Biochemical studies
Test Timing Result Normal range
Random serum cortisol
(mmol·L−1) Day 1 489 140–690
Random serum cortisol
(mmol·L−1) Day 1 (repeat) 362 140–690
Serum Aldosterone (pmol·L−1) Day 1 129 111–860
Serum Renin (mU·L−1) Day 1 20 8.3–46.3
24-hour urinary catecholamines
Noradrenaline (nmol/24-hour) At 2 months 266 0–430
Adrenaline (nmol/24-hour) At 2 months 41 0–70
Dopamine (nmol/24-hour) At 2 months 1690 0–2700n
24-hour urinary metanephrines
Normetadrenaline (nmol/24-hour) At 2 months 2972 0–4900
Metadrenaline (nmol/24-hour) At 2 months 1293 0–2000
24-hour urinary catecholamines
Noradrenaline (nmol/24-hour) At 9 months 313 0–430
Adrenaline (nmol/24-hour) At 9 months 53 0–70
Dopamine (nmol/24-hour) At 9 months 1480 0–2700
24-hour urinary catecholamines
Noradrenaline (nmol/24-hour) At 18 months 133 0–430
Adrenaline (nmol/24-hour) At 18 months 35 0–70
Dopamine (nmol/24-hour) At 18 months 783 0–2700
24-hour urinary catecholamines collected on the day of surgery following the hypertensive crisis were also normal.
fentanyl.Similarepisodesoccurredontwofurtheroccasions,
and an esmolol infusion was given during these episodes
(total dose 200mg). Following removal of the tumour which
took approximately three hours altogether, there was no
further recurrence of hypertension and no hypotension. The
patient was extubated at the end of the procedure and re-
turned to a general surgical ward. She remained well until
her discharge from hospital two days later.
Histology of the adrenal gland, reported six days later,
showed that about half of it consisted of a distinct greyish-
redlesion.Histologyofthislesionshowedanarrangementof
small cells with hyaline globules, together with sustentacular
cells. This is characteristic of a phaeochromocytoma and is
known as a zellballen. The diagnosis was made by a pathol-
ogist experienced in the histology of adrenal glands.
3. Discussion
3.1.TheCase. Thispatientpresentedforsurgerywithadiag-
nosis of nonfunctioning adrenal adenoma. Phaeochromocy-
toma, Cushing’s syndrome, and Conn’s syndrome had been
ruled out by appropriate diagnostic tests, some of which had
been repeated on several occasions over several months of
tumour surveillance.
During mobilisation of the adrenal mass, she became
very hypertensive. The cause of this was not immediately
obvious, especially since we were working on the assumption
that phaeochromocytoma was not a possible diagnosis.
Persistence and recurrence of hypertension appeared to rule
out equipment malfunction, so our ﬁrst response was to
increase the inspired concentration of volatile agent and give
increments of opioid.Case Reports in Anesthesiology 3
Recurrence of hypertension despite these manoeuvres
prompted us to start an infusion of esmolol. With hindsight
this is not a logical choice since beta-blockade can worsen
hypertension in the presence of a phaeochromocytoma,
by opposing beta-adrenoceptor-activated vasodilatation in
skeletal muscle beds. However, we were working on the
assumption that this was deﬁnitely not a phaeochromocy-
toma and the priority was myocardial and cerebral protec-
tion in the face of severe hypertension. In the time it took to
reconsider the management, surgery was completed and the
b l o o dp r e s s u r eh a dr e t u r n e dt on o r m a l .
At the time we were not aware of the limited sensitivity
of 24-hour urine assays in the diagnosis of phaeochromocy-
toma. If we had been, we might have had a higher index of
suspicion and managed the hypertension with alpha-block-
ade (e.g., phentolamine) or other vasodilator (e.g., sodium
nitroprusside) [2].
3.2. Diagnostic Tests. The choice of diagnostic test is based
on the index of suspicion of phaeochromocytoma. Plasma
metanephrine has the highest sensitivity (96%) but lower
speciﬁcity(85%).Incomparison,24-hoururinarycatechola-
mines and metanephrines have a sensitivity of 87.5% and
a speciﬁcity of 99.7% [3]. The international consensus on
screeningrecommends24-hoururinarycatecholamineswith
or without urinary metanephrines as the standard screen-
ing tool [4]. The diagnosis should be considered in patients
(especially young patients) whose hypertension is diﬃcult to
control, or in whom there are other characteristic symptoms,
such as headache, palpitations, and sweating [5, 6]. There
are some groups of patients in whom the index of suspicion
is higher, and these include those with persistent hyperten-
sion, familial endocrine neoplasia syndromes, or suspicious
appearances on imaging [7]. It may then be appropriate to
also measure plasma free metanephrines [8, 9].
Our patient had none of the characteristic features of
phaeochromocytoma, instead presenting acutely with hae-
morrhage into the adrenal gland. She had an isolated blood
pressure reading in the hypertensive range, and this was
when she was in acute pain at her initial presentation. It
is not unknown for patients with phaeochromocytoma to
be normotensive [10], but safe management of these pa-
tientsstillrequirestreatmentwithalpha-blockingagentspre-
operatively. We believed that phaeochromocytoma had been
excluded in our patient by the ﬁnding of 3 normal 24-hour
urinary catecholamines and metanephrines [11, 12]. We
were not aware at that time that the usual guidelines do not
apply to asymptomatic patients; otherwise we might have re-
quested plasma metanephrine assay as well.
Theonlysuspiciousﬁnding,whichmighthaveprompted
further investigation, was the report of slightly atypical fea-
tures on the MRI scan. We were thus presented with a nor-
motensive patient who had had a diagnostic test within the
normalrangeon3occasions.Itwasdiﬃculttojustifyfurther
investigation.
Further Comment. During the process of obtaining written
consentfromthepatientforpublicationsofthiscase,shetold
us that she had actually had symptoms of headache, dizzi-
ness, and palpitations and had also self-measured her blood
pressure in the hypertensive range.
4. Conclusion
Negative urinary catecholamines in a histologically or imag-
ing-conﬁrmed phaeochromocytoma are not uncommon
[10],butherewepresentacaseoffailureofbothbiochemical
and imaging detection with obvious consequences. We pre-
sent this case in order to alert anaesthetists to the limitations
of diagnostic tests for phaeochromocytoma. Urinary cate-
cholamines may be a useful screening tool in symptomatic
patients, but if there is any doubt at all (e.g., atypical imag-
ing appearance), then further biochemical tests such as
plasma metanephrines should be done. It may also be ad-
visable to take a very careful history in case patients are not
forthcoming with symptoms.
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